106 related articles for article (PubMed ID: 22236016)
1. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
Lawrence J; Saba C; Gogal R; Lamberth O; Vandenplas ML; Hurley DJ; Dubreuil P; Hermine O; Dobbin K; Turek M
Vet Comp Oncol; 2012 Jun; 10(2):143-54. PubMed ID: 22236016
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
3. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
[TBL] [Abstract][Full Text] [Related]
4. In vitro chemosensitivity of feline injection site-associated sarcoma cell lines to carboplatin.
Maxwell EA; Phillips H; Schaeffer DJ; Fan TM
Vet Surg; 2018 Feb; 47(2):219-226. PubMed ID: 29120489
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma.
Saba CF; Vail DM; Thamm DH
Vet Comp Oncol; 2012 Dec; 10(4):283-91. PubMed ID: 22236148
[TBL] [Abstract][Full Text] [Related]
7. Influence of different cell storage/culture conditions on spontaneous proliferation and level of tyrosine kinase receptor inhibition in two feline injection-site sarcoma cell lines.
Feldhaeusser BR; Turek M; Lawrence J; Cornell K; Gogal RM
J Immunoassay Immunochem; 2013; 34(3):266-82. PubMed ID: 23656247
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
Holtermann N; Kiupel M; Hirschberger J
Vet Comp Oncol; 2017 Jun; 15(2):632-640. PubMed ID: 26762970
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
11. PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology.
Maniscalco L; Iussich S; Morello E; Martano M; Biolatti B; Riondato F; Della Salda L; Romanucci M; Malatesta D; Bongiovanni L; Tirrito F; Gattino F; Buracco P; De Maria R
Vet J; 2013 Jan; 195(1):41-7. PubMed ID: 22704137
[TBL] [Abstract][Full Text] [Related]
12. Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002).
Phelps HA; Kuntz CA; Milner RJ; Powers BE; Bacon NJ
J Am Vet Med Assoc; 2011 Jul; 239(1):97-106. PubMed ID: 21718202
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells.
Kowarik M; Onofri C; Colaco T; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):113-20. PubMed ID: 19373754
[TBL] [Abstract][Full Text] [Related]
15. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection.
Soroceanu L; Akhavan A; Cobbs CS
Nature; 2008 Sep; 455(7211):391-5. PubMed ID: 18701889
[TBL] [Abstract][Full Text] [Related]
18. Dimerization drives PDGF receptor endocytosis through a C-terminal hydrophobic motif shared by EGF receptor.
Pahara J; Shi H; Chen X; Wang Z
Exp Cell Res; 2010 Aug; 316(14):2237-50. PubMed ID: 20580638
[TBL] [Abstract][Full Text] [Related]
19. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
Wang Y; Mandal D; Wang S; Kleinerman ES; Pollock RE; Lev D; Hayes-Jordan A
Cancer; 2010 Aug; 116(16):3892-902. PubMed ID: 20564078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
